Cost of Albenza
Albenza is an anthelminthic drug. Its active substance is albendazole. The drug also has activity against pathogenic protozoa, effect on intestinal and tissue forms of parasites; actives against eggs, larvae and adult worms. Albenza is effective for most intestinal nematodosis and cestodoses (larval forms). Perhaps today we haven't another anti-parasitic drug with such a wide spectrum of action.
Albenza is an anthelminthic and antiprotozoal drug effective in the mono- and poly-invasion. It is especially effective against larval forms of cestodes - Echinococcus granulosus and Taenia solium, nematodes - Strongyloides stercolatis. The drug active substance is albendazole. Indications: neuro-cysticercosis, caused by the larval form of swine taenia; echinococcosis of the liver, lung, and peritoneum, caused by the larval form of the dog tape worm, and strongyloidiasis. Contraindications: hypersensitivity (including other benzimidazole derivatives), pathology of retina, pregnancy, lactation. Side effects: violations of the liver with the change in the functional liver tests (low or modest transaminase level increasing), oppression marrowy hematosis (lakopenia, granulocytopenia, agranulocytosis, thrombocytopenia, pancytopenia), increased body temperature, pain in the abdomen, nausea, vomiting, headache, dizziness, meningeal symptoms, high blood pressure, acute renal failure, alopecia, skin rashes, itching and other allergic reactions.
What are phleboliths and are they safe?
Phleboliths are small, round lumps of calcium that form inside a person's veins. This type of vascular calcification often occurs in the pelvic area and is more common with age. Phleboliths frequently develop in people over 40. On an X-ray, the lumps may be mistaken for kidney stones. Learn more about phleboliths here.Mon, 23 Apr 2018, 20:00
'Biomedical tattoo' might catch cancer early
Medical research is reaching a new frontier with implants that can accurately spot early signs of cancer. Yet the road from laboratory to patient is long.Sun, 22 Apr 2018, 10:00